Navigation Links
Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009
Date:11/13/2008

itional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward-Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at '/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
2. Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007
3. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
4. Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded
5. University Hospitals Case Medical Center, Cleveland, USA and Cardialysis BV, Rotterdam, the Netherlands Enter Strategic Alliance to Found Cardialysis Cleveland
6. NanoMedicine Summit Returns to Cleveland, September 25-26
7. Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- A new report by  visiongain  forecasts ... $22.4bn in 2019. That revenue forecast and others appear ... 2015-2025 ,  published in March 2015. ... forecasts and qualitative analyses of the antithrombotic drugs market. ... London, UK . It produces analyses ...
(Date:5/1/2015)... -- According to a new market ... by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), by ... Analysis & Global Forecast to 2019", published by ... Market for the forecast period of 2014 to ... Billion by 2019 from $1.425 Billion in 2014, ...
(Date:4/30/2015)... N.J. , April 30, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... results for the first quarter of 2015 on May ... Roka Bioscience will also host a conference ... 2015 to discuss its first quarter financial results. During ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has commenced an underwritten public ... to grant the underwriters a 30-day option to purchase ... of common stock offered in the public offering. The ... be no assurance as to whether or when the ...
Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... , , NEW ... announces that a new market research report is ... Future of Nutrigenomics: New opportunities in personalized nutrition ... , Nutrigenomics explores how nutrients or bioactive ...
... , ROCKVILLE, Md. , Feb. 16 ... focused on the development and commercialization of clinical-stage products for central ... fourth quarter and full year ended December 31, 2009 . ... for the fourth quarter of 2009, compared to $7.7 ...
... ... partnering with sponsors and CROs , ... Orlando, FL (PRWEB) February 16, 2010 -- Akaza Research is pleased ... 12-14 in Orlando, Florida. The event is being held at the Orlando World Center ...
Cached Biology Technology:Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 2Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 3Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 4Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 5Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 2Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 3Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 4Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 7Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 8Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 9Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 10Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 11Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 12Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 13Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 14Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 15Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 16Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 17Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results 18Akaza Research to Present OpenClinica Electronic Data Capture Software at Partnerships in Clinical Trials 2010 2
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... genetic clues into rheumatoid arthritis (RA), a chronic inflammatory ... yet known, RA has been linked to an inherited ... occurrence among siblings seems to be random. ... profiles in patients with RA, researchers at the University ...
... a new low-cost system that analyzes scattered laser light ... processing and homeland security at one-tenth the cost of ... Using Optical Scattering Technology - works by shining a ... in a nutrient medium. , "Unlike conventional methods, we ...
... vegetables, the other infecting humans - essentially use the ... the cells of their respective hosts. , That's what ... a study published in the current issue of the ... that the pathogen that causes malaria in humans and ...
Cached Biology News:New genes implicated in rheumatoid arthritis 2Purdue creates new low-cost system to detect bacteria 2Purdue creates new low-cost system to detect bacteria 3Purdue creates new low-cost system to detect bacteria 4Malaria, potato famine pathogen share surprising trait 2
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
... expression of an N-terminal FLAG® fusion and ... marker from bicistronic mRNA. Two genes ... for transcription of a single message from ... for protein-protein interaction studies, multi-subunit proteins, and ...
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
Biology Products: